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Fibroblast growth factor-21 (FGF21) is closely related to various metabolic and cardiovascular disorders. 
However, the direct targets and mechanisms linking FGF21 to blood pressure control and hypertension 
are still elusive. Here we demonstrated a novel regulatory function of FGF21 in the baroreflex afferent 
pathway (the nucleus tractus solitarii, NTS; nodose ganglion, NG). As the critical co-receptor of FGF21, 
β-klotho (klb) significantly expressed on the NTS and NG. Furthermore, we evaluated the beneficial 
effects of chronic intraperitoneal infusion of recombinant human FGF21 (rhFGF21) on the dysregulated 
systolic blood pressure, cardiac parameters, baroreflex sensitivity (BRS) and hyperinsulinemia in the 
high fructose-drinking (HFD) rats. The BRS up-regulation is associated with Akt-eNOS-NO signaling 
activation in the NTS and NG induced by acute intravenous rhFGF21 administration in HFD and control 
rats. Moreover, the expressions of FGF21 receptors were aberrantly down-regulated in HFD rats. In 
addition, the up-regulated peroxisome proliferator-activated receptor-γ and -α (PPAR-γ/-α) in the NTS 
and NG in HFD rats were markedly reversed by chronic rhFGF21 infusion. Our study extends the work 
of the FGF21 actions on the neurocontrol of blood pressure regulations through baroreflex afferent 
pathway in HFD rats.
The fibroblast growth factor-21 (FGF21) is a master regulator for its effects on metabolic, cardiovascular, and neu-
roendocrine systems1–3. The administration of exogenous FGF21 can therapeutically correct the dysregulation 
with metabolic reversions of systemic metabolism, energy expenditure and insulin sensitivity4–6. Furthermore, 
the FGF21-resistance mediated by FGFRs-klb down-regulation in the liver and white adipose tissues proposed 
by Fisher and colleagues provides the explanation for the conditions that serum levels of the beneficial FGF21 are 
elevated in various metabolic diseases7,8.
It has been demonstrated that FGF21 can specifically bind to the membrane fibroblast growth factor recep-
tors (FGFRs, FGFR1-4) that requires the expression of the trans-membrane protein β -klotho (klb) for signal 
transduction9. The biological signals of FGF21 are transduced by rapid phosphorylation of various downstream 
pathways, such as phosphorylation of Akt (protein kinase B) or extracellular mitogen-activated protein kinase 1 
and 2 (ERK1/2) signaling pathway9–11. Moreover, the metabolic effects of FGF21 are functionally interplayed with 
the expression and activation of peroxisome proliferator-activated receptor-γ and -α (PPAR-γ /-α )12–14.
Hypertension (HTN) is a common complication of metabolic abnormalities in cardiovascular system15,16. As 
reported previously, serum FGF21 levels are closely associated with the metabolic syndrome and high blood pres-
sure (hypertension)1,17. However, the direct downstream targets of FGF21 for the development of hypertension 
have not been revealed. It has been shown that FGF21 can cross the blood-brain barrier18, which raises a great 
possibility that FGF21 may act on the central nervous system3,19,20.
Notably, the baroreceptor reflex (baroreflex) afferent pathway, consisted of nucleus tractus solitarii (NTS) and 
nodose ganglion (NG), plays a key role in blood pressure modulation21–24. The defects in baroreflex function can 
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lead to hypertension associated with metabolic syndrome and obesity25,26, which is consistent well with the notion 
that altered FGF21 receptor expressions may be observed in the NTS and NG19. Therefore, it is logically important 
to confirm and determine the role of FGF21 in the neurocontrol of blood pressure regulation and its contribution 
to the metabolic syndrome-related pathogenesis of hypertension.
In this study, we used the high fructose-drinking induced hypertension rats as a metabolic syndrome-related 
hypertension model27,28, and investigated the effects of FGF21 on blood pressure regulation and baroreflex sen-
sitivity and the potential changes in expression profiles of FGFRs in baroreflex afferent pathway under disease 
condition.
Results
The Cardiovascular Effects of Chronic Intraperitoneal Infusion of Recombinant Human FGF21 in 
HFD Rats. Our preliminary data showed that the systolic blood pressure (SBP) and diastolic left ventricular 
internal diameter (LVIDd) were significantly increased in rats with four weeks high fructose-drinking (HFD, 
n = 42) compared to normal control (CTL, n = 8), rather than the body weight and the ratio of heart weight to 
body weight (HW/BW) (Figures S1 and 2).
Based on this fructose fed induced hypertensive model, we investigated the cardiovascular effects by chronic 
intraperitoneal infusions of recombinant human FGF21 (rhFGF21) in HFD rats. As shown in Fig. 1A, the SBP 
of HFD rats treated with rhFGF21 (HFD + rhFGF21) was significantly and continuously decreased along with 
rhFGF21 infusion (5 μ g/kg/day) during week 4, 5, and 6 compared to HFD groups (P < 0.01, respectively; n = 8 
for each group). Meanwhile, significant modification of SBP was not observed in normal control rats under the 
same experimental condition (CTL + saline vs. CTL, P > 0.05, n = 8 for each group) (Fig. 1A).
Furthermore, we tested the mean arterial pressure (MAP, mmHg), heart rate (HR, bpm) and baroreflex sensi-
tivity (BRS = Δ HR/Δ MAP, bpm/mmHg) of anesthetized rats by the protocol reported previously1. The reversal 
effect of rhFGF21 on the increased blood pressure in the HFD rats was also demonstrated by the notion of MAP 
baselines: HFD vs. CTL (n = 6–8) and HFD + rhFGF21-3w vs. HFD (n = 4–6, P < 0.01) (Fig. 1C). Meanwhile 
rhFGF21 infusions did not alter the HR baselines in the control or HFD rats (P > 0.05, n = 4–8) (Fig. 1B). 
Importantly, we further investigated the changes in BRS by means of intravenous injections of phenylephrine 
(PE) or sodium nitroprusside (SNP) at concentrations of 1, 3, or 10 μ g/kg (PE1/3/10 or SNP1/3/10) in HFD and 
rhFGF21 treated rats. Our data demonstrated for the first time that the aberrantly decreased BRS in HFD group 
was significantly reversed by chronic rhFGF21 infusion (HFD + rhFGF21-3w vs. HFD: PE 1, 3, and 10, P < 0.05 
or P < 0.01, respectively; SNP 1, 3 and 10, P < 0.05 or P < 0.01, respectively; n = 4–8) (Fig. 1D,E).
Figure 1. The cardiovascular protective effects of rhFGF21 administration (i.p) in HFD rats. (A) The SBP 
of control (CTL) and HFD rats with rhFGF21 infusion (i.p) for 3 weeks (3w), n = 8 for each group; (B,C) The 
MAP (mmHg) and heart rate (HR) baselines; (D,E) The BRS (bpm/mmHg) induced by PE or SNP-1/3/10 
(phenylephrine or sodium nitroprusside at concentration of 1, 3 or 10 μ g/kg). n = 4–8 for each group in (B–E). 
Results were analyzed using two-way ANOVA followed by Bonferroni’s post hoc test and averaged data were 
presented as mean ± SEM. * P < 0.05 and * * P < 0.01 vs. CTL + saline, †P < 0.05 and ††P < 0.01 vs. HFD + saline.
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In addition, the echocardiographic results in the parasternal long axis (PSLA) M-mode indicated that the 
enlarged LVIDd in the HFD rats (6.66 ± 0.09 mm) was reduced obviously at 3 weeks after rhFGF21 infusion 
(5.91 ± 0.17 mm) (Table 1).
To investigate the status of metabolism and sympathetic nervous system in rats, we tested the serum levels of 
insulin, and norepinephrine as an indirect but widely used indicator of sympathetic nerve activity (SNA)29,30. Our 
data from ELISA(enzyme linked immunosorbent assay) showed that the markedly elevated serum insulin and 
norepinephrine in HFD, were reversed in HFD + rhFGF21-3w group (n = 8) (Figure S3). Interestingly, the serum 
insulin was also significantly up-regulated in CTL + rhFGF21-3w compared to CTL group (n = 8) (Figure S3). 
The results above suggested the protective effects of chronic FGF21 infusion on systemic hyperinsulinemia and 
excessive sympathoactivation in HFD.
NTS and NG are Novel Targets for the Action of FGF21. To determine the direct targets of FGF21 
on blood pressure control through baroreflex afferent function, we firstly investigated the mRNA and protein 
expressions of klb in the NTS and NG (Fig. 2). Our results from immunohistochemistry and whole section visual-
ization showed that klb significantly expressed on the cell membrane of NG neurons, n = 8 duplications (Fig. 2A) 
and NTS regions, n = 6 duplications (Bregma − 12.60 mm, the 6th edition, Paxinos and Watson, 2007) (Fig. 2B). 
Meanwhile, the Klb peptide blocking dot blot assay was performed to confirm the specificity of Klb protein 
immunostaining in NTS with LI-COR fluorescent-imaging (Figure S4). Furthermore, the mRNA expressions 
of Klb and FGFR1-4 in the NTS and NG tissues were confirmed by qRT-PCR detection (n = 3–6 duplications) 
(Fig. 2C).
The Direct Effect of FGF21 on the Modifications of BRS Associated with the Signaling 
Activation in the NTS and NG. The results above indicated that NTS and NG (baroreflex afferent pathway) 
are potential targets for the FGF21 action on neurocontrol of circulation (Figs 1 and 2), whereas, it is essential 
to confirm the direct effect of the FGF21 on the BRS control associated with baroreflex afferent pathway. To test 
this hypothesis, we administered rhFGF21 (1 μ g/rats) intravenously (i.v) to rats, and continuously monitored the 
MAP for one hour under a stable anesthesia (3% amobarbital sodium, 25 mg/kg, i.p). Our data indicated that 
the MAPs were not significantly changed in normal control or HFD rats under this condition (Fig. 3A) (HFD 
+ rhFGF21 vs. HFD, P > 0.05; CTL + rhFGF21 vs. CTL, P > 0.05, n = 5 for each group). As in the traditional 
protocol, the BRS of rats was usually tested under stable anesthesia28,31,32. In order to exclude the possible effect 
of amobarbital sodium on blood pressure under current situation, an equivelent volume saline was applied at 10, 
30, and 60 min (Figure S5) in normal rats and the stable BRS conditions were achieved in anesthesized rats with 
3% amobarbital sodium (25 mg/kg, i.p), suggesting that the applied dosage of amobarbital sodium would not 
influence the following tests with rhFGF21 on blood pressure. Appearently, our results indicated that the BRS 
was dramatically elevated by acute rhFG2F1 injections (i.v). In normal control rats, the BRS (relative to basline, 
fold) was 1.48 ± 0.11, 2.51 ± 0.20, and 1.53 ± 0.19 fold, respectivily, at 10, 30, and 60 min after rhFGF21 injections 
(P < 0.05, n = 5 for each group). While, in HFD rats, the increased BRS was only observed at 30 min (1.61 ± 0.07 
vs. basline, P < 0.05, n = 5) after rhFGF21 treatment (Fig. 3B). In addition, the changes in Δ HR were similar to 
BRS (Figure S6).
Previous studies demonstrated that the Akt-eNOS(endothelial nitric oxide synthase)-NO(nitric oxide) path-
way is the key signaling in blood pressure control in the NTS33, while Akt is also an important target of FGF21. 
Thus, to invesitigate the actions of acute rhFGF21 (i.v) infusion on NTS and NG, the Akt-eNOS-NO activations 
were also tested at the same time period. Our data showed that the phosphorylated levels of Akt and eNOS were 
significantly up-regulated compared with baselines at 10, 30, and 60 min in the NTS, and at 10 min in NG after 
acute rhFGF21 injections (i.v) in normal control rats (Fig. 3). In accordance with the Akt-eNOS signaling acti-
vation, the NO levels in the NTS at 10 min after acute rhFGF21 infusion were significantly elevated 2.28 fold in 
normal control rats, and 1.26 fold in HFD rats (Fig. 3). Whereares, the hypertensive agent superoxide (SO) in the 
NTS didn’t changed with the actions of rhFGF21 in normal control or HFD (Figure S6). Interestingly, the serum 
insulin was increased in normal control rats only after 60 min actions of FGF21, but didn’t changed in HFD rats, 
PSLAX M-Model 
Parameters
CTL + saline 
(n = 9)
HFD + saline 
(n = 11) HFD + rhFGF21-3w (n = 4) CTL + rhFGF21-3w (n = 5)
IVSd (mm) 1.94 ± 0.10 1.76 ± 0.02 1.79 ± 0.08 2.07 ± 0.12
IVSs (mm) 3.08 ± 0.12 2.88 ± 0.06 2.86 ± 0.07 3.36 ± 0.19
LVIDd (mm) 6.15 ± 0.19 6.66 ± 0.09* 5.91 ± 0.17† 6.34 ± 0.24
LVIDs (mm) 3.07 ± 0.12 3.49 ± 0.19 2.95 ± 0.24 3.34 ± 0.22
LVPWd (mm) 1.99 ± 0.07 2.15 ± 0.07 1.76 ± 0.11 2.49 ± 0.25
LVPWs (mm) 3.18 ± 0.11 3.21 ± 0.14 2.74 ± 0.25 3.36 ± 0.01
EF (%) 79.6 ± 2.54 74.6 ± 2.37 79.8 ± 2.99 77.4 ± 2.77
FS (%) 49.7 ± 2.53 44.9 ± 2.33 50.3 ± 3.22 47.4 ± 2.63
Table 1.  Cardiac Parameters of rhFGF21 Administration in HFD Rats. All data are presented as 
mean ± SEM. PSLAX, parasternal long axis; LVIDs/LVIDd, systolic/diastolic left ventricular internal 
diameter, IVSs/IVSd, systolic/diastolic left ventricular septum thickness; LVPWs/LVPWd, systolic/diastolic 
left ventricular posterior wall; EF, ejection fraction; FS, fractional shortening. CTL: control rats; HFD: high 
fructose-drinking rats; rhFGF21-3w: intraperitoneal infusion of rhFGF21 for 3 weeks. Group sizes are as n 
animals. * P < 0.05 vs. CTL; †P < 0.05 vs.HFD.
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while the serum norepniphrine reducted only after 60 min of rhFGF21 action in HFD rats, but didn’t changed in 
normal control rats (Figure S3).
The Expression of FGF21 and Its Receptors in the Liver of HFD Rats. The dysregulation of FGF21 
and its receptors in the liver were reported previously in obesity and insulin resistant rats7. The results above 
demonstrated the cardiovascular beneficial effects and the modifications of baroreflex afferent function by 
rhFGF21 administration in HFD rats, while the pathological status of FGF21 in HFD rats is unrevealed. In this 
study, our data showed an approximate 25 folds higher of FGF21 mRNA expression in the liver in HFD rats 
(n = 9) compared to control rats (n = 6, P < 0.05) (Fig. 4A). Moreover, the mRNA and protein levels of FGFR2 
(P < 0.01, n = 6 for mRNA and protein ) and FGFR3 (P < 0.05, n = 3 for mRNA and P < 0.01, n = 6 for protein) 
Figure 2. The distribution of Klb protein on the NG and NTS. (A) Klb protein was detected by 
immunostaining of NG tissues sections (7 μ m). DAPI staining indicates nuclei (blue). The scale bar represents 
50 μ m, n = 8 duplications. (B) The immunostaining of whole brainstem section (35 μ m; Bregma, − 12.60 mm) 
showed the distribution of klb protein on NTS regions, n = 6 duplications, the scale bar represents 2 mm.  
(C) The mRNA expression levels of Klb and FGFR1-4 in the NTS and NG of normal rats, n = 3–6 duplications. 
The condition with no primary antibody was set as the negative control. 4V, 4th ventricle; sol, solitary tract; SolL 
nucleus of the solitary tract (Sol), -lateral part; SolVL, -ventrolateral part; SolV, -ventral part; SolM, -medial 
part; SolDM, -dorsomedial part; SolIM, -intermediate part.
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were significantly decreased in HFD groups (Fig. 4B,C), strongly suggesting that the HFD rats underwent a clear 
FGF21-resistant condition as reported previously7,8.
The Dysregulation of FGF21 Receptors in Baroreflex Afferent Pathway in HFD Rats. The effects 
of FGF21 are dependent on the expression levels of its receptors7,8. Thus, it was essential to further investigate the 
expression of klb and FGFR1-4 in the baroreflex afferent pathway in HFD rats.
In the NTS tissues, results from qRT-PCR showed the significant mRNA down-regulations of both FGFR2 
and FGFR3 (P < 0.05, n = 7 and 9 duplications, respectively), while the similar alternations were not confirmed 
for klb, FGFR1, and FGFR4 in HFD model rats (Fig. 5A). The protein detection results were consistent well 
with the changes in mRNA levels. The difference of klb protein expression was also not observed in HFD group 
Figure 3. The acute intravenous rhFGF21 injections in HFD rats. (A) The MAP after rhFGF21 injection 
(i.v) within 1 hour, n = 5 for each group. (B) The BRS (PE, 3 μ g/kg) change relative to basline (fold) at 10, 30 
and 60 min after rhFGF21 injection, n = 5–6 for each group. (C) The Akt signal activation in the NTS at 10, 30 
and 60 min after the rhFGF21 injections (i.v), n = 3–4 duplications from 12–15 rats for each group. (D) The 
eNOS signal activation in the NTS, n = 4 duplications from 12–16 rats for each group. (E) The nitric oxide (NO) 
concentrations in the NTS ( n = 8 for each group). (F) The Akt signal activation in the NG at 10, 30 and 60 min 
after the rhFGF21 injections (i.v), n = 3–4 duplications from 12–15 rats for each group. p-, phosphorylated; t-, 
total. Results were analyzed using two-way ANOVA followed by Bonferroni’s post hoc test, and averaged data 
were presented as mean ± SEM. NS, not significant, * P < 0.05 vs. baseline. Gels have been cropped for clarity; 
the bands were confirmed by the comparison with full-length gel images (Supplementary Figure S7) and 
molecular weight.
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(P > 0.05, n = 3 duplications) (Fig. 5B), but the proteins for FGFR2 and FGFR3 significantly decreased (P < 0.01, 
n = 6 duplications; P < 0.05, n = 4 duplications, respectively).
In the NG tissues, the mRNA (P < 0.01, n = 5 duplications) and protein (P < 0.05, n = 3 duplications) expres-
sions of FGFR2 were significantly down-regulated; but the mRNA and protein levels of klb, and mRNA levels of 
FGFR 1, 3, and 4 were normal (Fig. 5C,D).
The Genetic Modifications of PPAR-γ and -α in the NTS and NG by Chronic rhFG2F1 Infusion 
in HFD Rats. The PPAR-γ and -α are closely associated with the actions of FGF21 in various biological func-
tions12–14. Our results demonstrated that the mRNA levels of PPAR-γ and -α in the NTS and NG significantly 
up-regulated in HFD rats (HFD + saline vs. CTL saline, NTS: P < 0.01 for PPAR-γ and -α ; NG: P < 0.01 for 
PPAR-γ and P < 0.05 for PPAR-α ) (Fig. 6). Meanwhile, the chronic rhFGF21 infusion (5 μ g/kg/day) signifi-
cantly reversed the increased levels of PPAR-γ and -α (HFD + saline vs. HFD + rhFGF21-3w, NTS: P < 0.05 for 
PPAR-γ, while P > 0.05 for PPAR-α ; NG: P < 0.05 for PPAR-γ and P < 0.01 for PPAR-α , n = 4 duplications from 
8–12 rats for each group) (Fig. 6).
Discussion
The high fructose treated rats used in this research showed significant hypertension with impaired BRS, hyper-
insulinemia and elevated SNA (serum NE increased). Meahwhile, the pharmacotherapeutic experiments in vivo 
have revealed the beneficial effects on blood pressure (SBP and MAP) and BRS in HFD rats by three weeks 
chronic intraperitoneal rhFGF21 infusion (Fig. 1). In addition, the markedly increased SBP (afterload) and 
LVIDd (preload) in HFD, were both reduced by chronic rhFGF21 infusion. Therefore, the reduction of SBP 
and LVIDd by chronic rhFGF21 treatment may be induced by its effects on sympathoinbition (SNA/serum NE 
decreased) and BRS improvement.
For a long time, the direct targets and mechanisms of blood pressure control by FGF21 actions haven’t been 
reported, and it may be contributed by its effects on metabolism (hyperinsulinemia) and/or actions on baroreflex 
Figure 4. The mRNA and protein levels in the liver of HFD rats. (A) The mRNA expression of FGF21 in  
the liver of HFD (n = 9) and normal control rats (n = 6). (B) The FGFR1–4 and klb mRNA levels (n = 3–6).  
(C) The protein levels of klb, FGFR2 and FGFR3 protein (n = 6). Results were analyzed using two-tailed 
unpaired Student’s t-test, and averaged data were presented as mean ± SEM. * P < 0.05 and * * P < 0.01 vs. 
CTL. The gels have been run under the same experimental conditions. Full-length blots were presented in 
Supplementary (Figure S7).
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and sympathetic nerve. Whereas, our data in this study fully supported our hypothesis by the notion of the func-
tional expressions of klb and FGFRs proteins in the NG and NTS regions (Figs 2 and 5), and these results are 
the major findings of the current investigation and fundamental base leading to the investigation on the roles of 
FGF21 in the neurocontrol of circulation and blood pressure regulation. FGF21 ameliorated the hypertension and 
BRS impairment in HFD, which may be mediated by its receptors located in baroreflex afferent pathway.
Of note, the BRS (Δ HR/Δ MAP) represents the function and ability of baroreflex to control blood pressure, 
and it may contribute to the modifications on the changes in blood pressure and heart rate31,32,34, therefore, the 
increase of BRS actually doesn’t mean the activation of baroreflex or sympathoactivation. In this study, despite 
no alteration was observed for the MAP by an acute intravenous rhFGF21 injections in control and HFD rats, 
the BRS and Δ HR were increased within one hour, with Δ MAP didn’t changed (Figs 3 and S6). Thus, the sys-
temic rhFGF21 administration may cause complex effects on cardiovascular system in acute injections with BRS 
improvement, and it may not have direct and acute effects on the blood pressure regulation as other vasoactive 
drugs. Whereas, the Akt signaling is an important downstream target of the FGF21 actions in the brain neurons 
for the neuroprotective effects20, moreover, the Akt-eNOS signaling was demonstrated as a central pathway for 
baroreflex and blood pressure control in the NTS35,36. We demonstrated that the rapid and significant phospho-
rylation of Akt-eNOS, and the increase of NO level in the NTS were induced by acute injection of rhFGF21 
within one hour (Fig. 3). In addtion, the Akt-eNOS-NO signaling pathway in the NTS has been widely reported 
to be involved in the neuroexcitation modification or blood pressure regulation35,36, therefore, the obviously 
up-regulated BRS by acute rhFGF21 infusion in rats, is partially related to the activation of Akt-eNOS-NO path-
way in the NTS (Fig. 3), but independent to the levels of serum insulin and superoxide in the NTS (Figures S3 
and S6).
The metabolic effects of FGF21 are functional interplayed with the activation of PPAR-γ /-α 12–14. In addi-
tion, the previous reports demonstrated that the PPAR-γ was dysregulated in nodose ganglion neurons or ros-
tral ventrolateral medulla (RVLM) neurons in high fat diet or spontaneously hypertensive rats, respectively37,38. 
Figure 5. The dysregulation of FGFRs-Klb at mRNA and protein levels in the NTS and NG in HFD rats. 
(A) The klb and FGFR1–4 mRNA levels in the NTS tissues of HFD and control group rats (n = 6–9 duplications 
from 18–27 rats for each group). (B) The protein levels for klb (n = 3 duplications from 12–15 rats for each 
group), FGFR2 (n = 6 duplications from 24–30 rats for each group) and FGFR3 (n = 4 duplications from 14–20 
rats for each group) in NTS. (C) The klb and FGFR1–4 mRNA levels in the NG tissues of HFD and control 
group rats (n = 5 duplications from 20–25 rats for each group). (D) The klb and FGFR2 protein expression in 
the NG (n = 3 duplications from 15–18 rats for each group). Results were analyzed using two-tailed unpaired 
Student’s t-test, and averaged data were presented as mean ± SEM. * P < 0.05 and * * P < 0.01 vs. CTL. The gels 
have been run under the same experimental conditions. Full-length blots were presented in Supplementary 
(Figure S7).
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Furthermore, PPARs contribute to the blood pressure control via the central nervous system by the modifications 
of oxidative stress in neurons38. In this study, we demonstrated that the aberrantly up-regulated PPAR-γ and -α 
in the NTS and NG of HFD rats were markedly reversed by chronic rhFGF21 infusion (Fig. 6). Thus, the PPAR-γ 
and -α pathway in the NTS and NG may be involved in the protective effects of rhFGF21 on the increased SBP 
and impaired BRS in HFD rats.
FGF21-resistance mediated by FGFRs-klb down-regulation in the peripheral metabolic and hypothalamus 
tissues was demonstrated recently7,8. In our study, the FGFRs down-regulation in the NG and NTS regions of 
the HFD rats is partially indicated by the expression profiles of mRNA and protein in the current observations 
(Fig. 5). Meanwhile, the up-regulated NO level in the NTS by acute rhFGF21 injections induced Akt-eNOS sig-
naling activations, was only 1.26 fold in HFD, which was lower than 2.28 fold in normal control rats (Fig. 3). 
Moreover, the FGF21-resistant status has also been demonstrated in the liver tissues, which is supported by the 
notion that the FGF21 mRNA is markedly up-regulated, while FGFR2 and FGFR3 mRNA and protein are signif-
icantly down-regulated in the HFD rats (Fig. 4). Therefore, the FGF21-resistance in baroreflex afferent pathway 
might also be an important aspect to understand the pathogenesis of the metabolic disorder related hypertension, 
and it is attractive to investigate the role of FGF21 on hypertension by receptors (klb-FGFRs) knockdown/knock-
out in the NTS or NG in further investigation.
FGF21 can penetrate the blood brain barrier to act on the central nervous system (CNS)3,18. Previous stud-
ies have demonstrated the regulatory effects on neuroendocrine, neuroprotection and central metabolism con-
trol induced by FGF21 actions on hypothalamus and other CNS areas3,19,20. Recently, it was revealed that the 
stimulation of SNA to brown adipose tissue was induced by the actions of FGF21 in brain, depending on the 
corticotropin-releasing factor39. Whereas, the corticotropin-releasing factor depended sympathoactivation 
induced by FGF21 or leptin only regulated its thermogenic functions, but didn’t modificated on cardiovascu-
lar actions39,40. Thus, the autonomic functions by central actions of FGF21 is not clarified well and still needs 
further research. Even though, our immunohistochemistry suggested that klb may widely distributed in brain-
stem (immuno-positive areas), but whether the FGF21 could act on other autonomic function areas in CNS also 
needs further evidences to demonstrated in future, such as FGF21 receptors expressions, signaling activations 
and functions.
On the basis of above results, it is attractive to investigate the role of FGF21 on hypertension by gene knock-
down or knockout of FGF21 receptors (klb-FGFRs) in the NTS and NG in further investigation. Whereas, the 
findings of this study indicated that the NTS and NG are the novel and direct targets of the central FGF21 action 
for the blood pressure control associated with baroreflex afferent pathway.
Methods
Animals. Male Sprague-Dawley (SD) rats weighting 200–220 g were purchased from the experimental animal 
center of the Second Affiliated Hospital of Harbin Medical University (Harbin, China).
All animal protocols were pre-approved by the Institutional Animal Care and Use Committee at Harbin 
Medical University, which are in accordance with the recommendations of the Panel on Euthanasia of the 
American Veterinary Medical Association and the National Institutes of Health publication “Guide for the Care 
and Use of Laboratory Animals”.
High fructose-drinking induced Hypertension in Rats. Rats were randomly housed in groups of 3–4 
rats per cage in a controlled environments (25 °C with 12 hours light/dark cycles). According to the previous 
Figure 6. The expression of PPAR-γ and -α in the NTS and NG in chronic rhFGF21 infusion rats. The 
mRNA levels of PPAR-γ and -α in the NTS and NG in HFD + saline, CTL + saline and HFD + rhFGF21–3w 
(5 μ g/kg/day, 3 weeks, i.p) rats. n = 4 duplications from 8–12 rats for each group. Results were analyzed using 
one-way ANOVA followed by Bonferroni’s post hoc test, and averaged data were presented as mean ± SEM. NS, 
not significant, * P < 0.05 and * * P < 0.01 vs. CTL + saline; †P < 0.05 and ††P < 0.01 vs. HFD + saline.
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reports27,41, rats recevied standard rat chow and tap water (Control group, CTL), or water containing 10% (weight/
volume) fructose (high fructose-drinking group, HFD) for 4–5 weeks. The systolic blood pressure of rats for each 
group was recorded weekly.
Systolic Blood Pressure Measurements. The non-invasive systolic blood pressure (SBP, mmHg) of all 
rats were measured weekly. The SBP was measured in conscious rats with a manometer-tachometer (BP-2010E, 
Softeron Biotechnology, Beijing, China) using the tail-cuff method. Rats were placed in a plastic holder under a 
36 °C temperature-controlled quiet environment. The average value of SBP for each rat was obtained from five 
SBP readings after the rats were acclimated to the environment.
Echocardiographic Measurements. Trans-thoracic echocardiography with an ultrasound machine (Vevo 
2100 imaging system, VisualSonics, Toronto, Canada) was used to test the heart functions of rats. Left ventricu-
lar systolic/diastolic internal diameter (LVIDs/LVIDd, mm), interventricular septum systolic/diastolic thickness 
(IVSs/IVSd, mm) and Left ventricular systolic/diastolic posterior wall (LVPWs/LVPWd, mm) were measured, 
and ejection fraction (EF, %) and fractional shortening (FS, %) were calculated from the short axis (SAX) or par-
asternal long axis (PSLAX)-mode recording.
Baroreflex Sensitivity Detection. By following the protocol31,32, the mean arterial pressure (MAP, 
mmHg), heart rate (HR, bpm) and baroreflex sensitivity (BRS) of anesthetized (3% amobarbital sodium, 25 mg/
kg, i.p) rats were tested by cannulas of arteria (left, for artery pressure detection) and vena (right, for drug admin-
istration) femoralis and electrocardiographic (ECG) recording (LabChart 7 Pro software, ADinstruments, 
Australia) with body temperature maintained at approximately 35 °C. BRS was established by intravenous bolus 
injections of phenylephrine (PE, Sigma, USA) or sodium nitroprusside (SNP, Sigma, USA) at an incremental dose 
(1 μ g/kg, 3 μ g/kg and 10 μ g/kg), respectively, and 15 to 20 minutes was given before the next injection. The maxi-
mum changes in HR and the associated MAP were calculated as BRS (Δ HR/Δ MAP, bpm/mmHg).
Chronic intraperitoneal infusions of rhFGF21 in HFD Rats. Rats were subjected to intraperitoneal 
infusions of 0.9% sterile saline (HFD + saline) or rhFGF21 (5 μ g/kg/day, HFD + rhFG2F1) for 3 weeks after 2 
weeks of high fructose-drinking, and the access to fructose-drinking continued. Meanwhile, the control rats were 
subjected to infusions of 0.9% sterile saline (CTL + saline) or rhFGF21 (5 μ g/kg/day, CTL + rhFG2F1) at the 
same time. The rhFGF21 (CYT-281) was purchased from ProSpecBio (East Brunswick, NJ, USA).
Acute intravenous rhFGF21 injections in HFD rats. After 4 weeks of high fructose-drinking or normal 
fed, the anesthetized rats were subjected to femoral artery and vein catheters to record mean arterial pressure 
(MAP), and injects drug, respectively. After intravenous rhFG2F1 (1 μ g/rats) or 0.9% sterile saline injections, 
MAP (mmHg) was monitored continuously for one hour. Meanwhile, the BRSs (Δ HR/Δ MAP, bpm/mmHg) 
induced by phenylephrine (PE, 3 μ g/kg) were detected before (BRS basline) or after injections (at 10, 30 and 
60 min) in HFD and control rats.
Preparation of tissues. The nodose ganglia and liver tissues were isolated from each group rats as pre-
viously described by our laboratory method24,42; meanwhile the bilateral NTS were dissected with 1 mm inner 
diameter from a brainstem section (1 mm thick) at the level of the obex under a microscope43.
Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR). One mRNA sample of NG or NTS 
tissues was extracted from 4–5 rats in the same group (control or HFD). All primers used see the Table S1. The 
mRNA expression was determined using SYBR Green reagent in ABI 7500 Real-Time PCR System (Applied 
Biosystems). Data of relative gene expression were analysed with 2−ΔΔCT method44.
Immunoblotting Analysis. Total proteins were prepared by homogenizing the isolated NTS, NG or liver 
tissues for 1 hour at 4 °C in RIPA buffer containing Protease Inhibitor Cocktail. One protein sample of NG or NTS 
tissues was extracted from 4–5 rats in the same group. Protein extracts (100 μ g/sample, accessed through a BCA pro-
tein assay) were subjected to 10% SDS-Tris glycine gel electrophoresis and then transferred (Bio-Red Laboratories, 
USA) to a nitrocellulose membrane. The membranes were blocked in 5% non-fat dry milk/PBS buffer for 2 hours, 
and then incubated at 4 °C overnight with the primary antibodies (1:200–1:500): anti-GAPDH (internal control, 
Sigma, USA), anti-klb/anti-FGFR3 (Santa Cruz, USA), anti-FGFR1/anti-FGFR4 (Sigma, USA), anti-FGFR2 
(Abcam, USA), anti-p-Akt/anti-t-Akt and anti-p-eNOS/anti-t-eNOS (Cell Signaling Technology, USA), then the 
appropriate secondary anti-bodies (1:8000; LI-COR Biosciences, Lincoln, NE) were used at room- temperature for 
1 hour. The results were detected and analysed via odyssey system (LI-COR Biosciences, Lincoln, NE).
Measurements of Nitric Oxide and Superoxide Levels in the NTS. The levels of nitric oxide and 
superoxide anion in isolated NTS tissues were measured using Nitric Oxide kit ( Griess reagent, S0021) and 
Superoxide assay kit (WST-1, S0060), respectively ( Beyotime institute of Biotechnology, China).
Enzyme Linked Immunosorbent Assay(ELISA). The serum insulin and norepinephrine concentrations 
of rats were measured by using ELISA kits (E-EL-R2466c and E-EL-0047c, respectively; Elabscience, China).
Immunohistochemistry and Whole Section Visualization. The immunohistochemistry protocol for 
NG was described by our previous reports24,45: Horizontal sections of 7 μ m thickness were collected for later klb 
protein staining (anti-klb, 1:100, Santa Cruz, USA).
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Whereas, for the whole section visualization of NTS46, rats were anesthetized with 3% amobarbital sodium 
(25 mg/kg, i.p), then transcardially perfused for 10 minutes with 4% paraformaldehyde (PFA). Harvested brains 
were placed in 4% PFA overnight before transferred to 30% sucrose and rotated for 24~48 hours at 4 °C. Coronal 
brainstem sections (35 μ m thickness, Bregma − 12.6 mm) were cut on a freezing microtome (Leica Biosystem, 
Germany) and stored in − 80 °C. Brainstem sections were washed in PBS for 10 minutes each before immunos-
taining, and blocked in 4% normal goat serum/0.3% Triton X-100/PBS for 1 hour at room temperature. For 
labeling, the sections were incubated with primary antibody overnight at 4 °C: anti-klb (Santa Cruz, USA) at a 
dilution of 1:200 in blocking solution. Then the sections were washed three times with PBST for 10 minutes each, 
and incubated in the appropriate secondary antibody (anti-goat IRDye 800CW) at a dilution of 1:5000 in PBS 
(LI-COR Biosciences, Lincoln, NE) at room temperature for 1 hour. All sections washed five times in PBST for 
10 minutes each. And then fluorescent-imaging was detected using a LI-COR Odyssey infrared imager (21 μ m 
resolution, 1 mm offset at the highest quality).
Statistical Analysis. All data were presented as mean ± SEM. Statistically significant differences among 
more than two groups were analysed with one or two-way ANOVA followed by Bonferroni’s post hoc test, and the 
two-tailed unpaired Student’s t-test was used where is appropriate. The criterion for statistical significance was 
set at P < 0.05.
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